Liver transplantation in Jehovah's Witnesses patients in a center of northeastern Brazil.

CONTEXT: Liver transplantation has been accepted as a therapeutic option for patients with end-stage liver disease and acute liver failure. Currently, Brazil has a well-established public organ transplant program, performing 7,425 solid organs transplants in 2012 alone, among which 1,595 were liver transplants. Jehovah's Witnesses report 7,6 million members worldwide. For religious reasons they refuse transfusion of whole blood or its primary components (red cells, fresh frozen plasma, platelets). OBJECTIVE: This study aims to present the results obtained with Jehovah's Witnesses patients by a liver transplantation service. METHOD: We conducted a retrospective review of medical records from Jehovah's Witnesses patients (n=4) who underwent orthotopic liver transplantation from September 2009 to September 2011 at the Walter Cantídio University Hospital of the Federal University of Ceará, Fortaleza, CE, Brazil. Coagulation parameters such as Hemoglobin, Hematocrit, Platelets, INR were evaluated during the preoperative, immediate postoperative, postoperative day (POD) 7 and POD 30. RESULTS: Coagulation parameters were expressed as means: hematocrit, 35.07%±6.65%, 24.6%±4.74%, 19.85%±2.10%, 31.85%±5.99%; hemoglobin, 12.57 g/dL±2.22, 8.92 g/dL±1.75, 6.92 g/dL±0.58, 11.17 g/dL±0.9; platelets, 160,975 mm3±148000, 128,000 mm3±34836, 65,000 mm3±33496, 234,250 mm3±287003 and INR, 143±0.10, 2.4±0.34, 1.24±0.10, 1.14±0.09. CONCLUSION: Liver transplantation can successfully be performed in Jehovah's Witnesses patient population provided that: 1) the medical team has extensive expertise in that field, 2) the patient has an adequate level of hematologic factors preoperatively, and 3) there is availability of specialized equipment such as cell saver to minimize blood loss and thus avoid transfusion requirements.

Liver transplanaation in jehovah's witnesses patients in a center of northeastern Brazil

Context Liver transplantation has been accepted as a therapeutic option for patients with end-stage liver disease and acute liver failure. Currently, Brazil has a well-established public organ transplant program, performing 7,425 solid organs transplants in 2012 alone, among which 1,595 were liver transplants. Jehovah's Witnesses report 7,6 million members worldwide. For religious reasons they refuse transfusion of whole blood or its primary components (red cells, fresh frozen plasma, platelets). Objective This study aims to present the results obtained with Jehovah's Witnesses patients by a liver transplantation service. Method We conducted a retrospective review of medical records from Jehovah's Witnesses patients (n = 4) who underwent orthotopic liver transplantation from September 2009 to September 2011 at the Walter Cantídio University Hospital of the Federal University of Ceará, Fortaleza, CE, Brazil. Coagulation parameters such as Hemoglobin, Hematocrit, Platelets, INR were evaluated during the preoperative, immediate postoperative, postoperative day (POD) 7 and POD 30. Results Coagulation parameters were expressed as means: hematocrit, 35.07% ± 6.65%, 24.6% ± 4.74%, 19.85% ± 2.10%, 31.85% ± 5.99%; hemoglobin, 12.57 g/dL ± 2.22, 8.92 g/dL ± 1.75, 6.92 g/dL ± 0.58, 11.17 g/dL ± 0.9; platelets, 160,975 mm 3 ± 148000, 128,000 mm 3 ± 34836, 65,000 mm 3 ± 33496, 234,250 mm 3 ± 287003 and INR, 143 ± 0.10, 2.4 ± 0.34, 1.24 ± 0.10, 1.14 ± 0.09. Conclusion Liver transplantation can successfully be performed in Jehovah's Witnesses patient population provided that: 1) the medical team has extensive expertise in that field, 2) the patient has an adequate level of hematologic factors preoperatively, and 3) there ...

Contexto O transplante hepático tem sido aceito como opção terapêutica para a doença hepática terminal e falência hepática aguda. Atualmente, o Brasil dispõe de um programa bem estabelecido de transplantes de órgãos, oferecido a toda população, realizando 7.425 transplantes de órgãos sólidos apenas em 2012, destes, 1.595 foram transplantes de fígado. Os membros da crença testemunhas de Jeová totalizam 7,6 milhões em todo o mundo. Por questões religiosas rejeitam transfusão de sangue e seus componentes primários (hemácias, plasma fresco congelado, plaquetas). Objetivo Este estudo visa apresentar os resultados obtidos em pacientes testemunhas de Jeová por um centro de transplante de fígado. Método Realizou-se análise retrospectiva dos registros médicos dos pacientes testemunhas de Jeová (n = 4), que realizaram transplante ortotópico de fígado de setembro de 2009 a setembro de 2011 no Hospital Universitário Walter Cantídio da Universidade Federal do Ceará. Parâmetros de coagulação como hemoglobina, hematócrito, plaquetas e International Normalized Ratio (INR) foram avaliados no pré-operatório, no pós-operatório imediato, no 7° e no 30° dia do pós-operatório. Resultados As médias dos parâmetros de coagulação expressaram-se, na cronologia descrita anteriormente, como segue: hematócrito, 35.07% ± 6.65, 24.6% ± 4.74, 19.85% ± 2.10, 31.85% ± 5.99; hemoglobina, 12.57 g/dL ± 2.22, 8.92 g/dL ± 1.75, 6.92 g/dL ± 0.58, 11.17 g/dL ± 0.9; plaquetas, 160,975 mm 3 ± 148000, 128,000 mm 3 ± 34836, 65,000 mm 3 ± 33496, 234,250 mm 3 ...

Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial.

OBJECTIVES: To evaluate the effect of association of tamsulosin/tadalafil taken daily compared with tamsulosin/placebo in the lower urinary tract with urodynamic study (UDS). METHODS: All patients underwent baseline UDS before randomization to tamsulosin 0.4 mg/tadalafil 5 mg (Group 1; n = 20) or tamsulosin 0.4 mg/placebo (Group 2; n = 20) once daily for 30 days. End-of-study UDS were performed on completion of the treatment period. The primary end point was to demonstrate changes in urodynamic variables in the voiding phase, detrusor pressure at maximum flow (PdetQmax), and maximum flow rate (Qmax), from baseline to week four. RESULTS: The primary outcome measure of this clinical trial, PdetQmax, showed a significant reduction in tamsulosin/tadalafil group (13 ± 17.0) compared to tamsulosin/placebo (-1.2 ± 14.35) group (P = 0.03). Qmax increased in both groups, tamsulosin/tadalafil (1.0 ± 2.4) and tamsulosin/placebo (1.4 ± 2.4), but the difference was not significant between treatment groups (P = 0.65). Total IPSS, storage, and voiding sub-score improved significantly in tamsulosin/tadalafil compared with tamsulosin/placebo group. CONCLUSIONS: The association of tamsulosin/tadalafil reduces detrusor pressure at maximum flow without changing the maximum flow rate during micturition and significantly improves lower urinary tract symptoms compared with the isolated use of tamsulosin.